AtriCure, Inc. (ATRC)

Market Cap	1.76B
Revenue (ttm)	447.57M
Net Income (ttm)	-38.92M
Shares Out	48.75M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	336,093
Open	36.21
Previous Close	36.34
Day's Range	35.25 - 36.28
52-Week Range	18.94 - 43.00
Beta	1.41
Analysts	Strong Buy
Price Target	43.11 (+19.65%)
Earnings Date	Oct 29, 2024

About ATRC

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensin...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 5, 2005
• Employees: 1,200
• Stock Exchange: NASDAQ
• Ticker Symbol: ATRC
• Website: https://www.atricure.com

Financial Performance

In 2023, AtriCure's revenue was $399.25 million, an increase of 20.84% compared to the previous year's $330.38 million. Losses were -$30.44 million, -34.49% less than in 2022.

Analyst Forecast

According to 9 analysts, the average rating for ATRC stock is "Strong Buy." The 12-month stock price forecast is $43.11, which is an increase of 19.65% from the latest price.

Price Target

$43.11

(19.65% upside)

Analyst Consensus: Strong Buy